Quantified Assessment of Deep Brain Stimulation on Parkinson’s Patients with Task fNIRS Measurements and Functional Connectivity Analysis: A Pilot Study

Ningbo Yu¹,²†, Siquan Liang³†, Jiewei Lu¹,²†, Zhilin Shu¹,², Haitao Li³, Yang Yu⁴, Jialing Wu⁴,⁵,⁶* and Jianda Han¹,²*

Abstract

Background: Deep brain stimulation (DBS) has proved effective for Parkinson’s disease (PD), but the identification of stimulation parameters relies on doctors’ subjective judgment on patient behavior.

Methods: Five PD patients performed 10-meter walking tasks under different brain stimulation frequencies. During walking tests, a wearable functional near-infrared spectroscopy (fNIRS) system was used to measure the concentration change of oxygenated hemoglobin (△HbO₂) in prefrontal cortex, parietal lobe and occipital lobe. Brain functional connectivity and global efficiency were calculated to quantify the brain activities.

Results: We discovered that both the global and regional brain efficiency of all patients varied with stimulation parameters, and the DBS pattern enabling the highest brain efficiency was optimal for each patient, in accordance with the clinical assessments and DBS treatment decision made by the doctors.

Conclusions: Task fNIRS assessments and brain functional connectivity analysis promise a quantified and objective solution for patient-specific optimization of DBS treatment.

Trial registration: The study was approved by the Ethical Committee of Tianjin Huanhu Hospital (2019-35), and has been registered in Chinese Clinical Trial Registry (ChiCTR1900022715).

Keywords: Deep brain stimulation programming; Parkinson’s disease; Brain efficiency; Functional connectivity

Background

Parkinson’s disease (PD) is a neurodegenerative disease caused by the progressive loss of nigrostriatal dopaminergic neurons in substantia nigra pars compacta [1]. The loss of dopaminergic neurons induces severe motor symptoms such as tremor, rigidity, bradykinesia and dyskinesia, as well as non-motor symptoms such as constipation, fatigue, anxiety, cognitive dysfunction and dementia [2, 3]. Deep brain stimulation (DBS) has proved an effective therapy for symptom improvement after PD, especially in the late stage when medication is less effective [4, 5].

With DBS operation, electrodes are implanted into specific target brain locations, such as the subthalamic nucleus or globus pallidus internal, as shown in Figure 1. The electrodes work as the neurostimulator and send electrical stimulation for the treatment of movement disorders [6, 7]. DBS programming, the identification of stimulation parameters of the implanted neurostimulator for symptom management, is crucial for successful and optimal treatment. However, the functioning neural mechanism of DBS remains unclear, and DBS programming in current clinical practice is typically conducted by doctors according to their observation of patient behavior, strongly relying on the doctors’ skill, experience, and subjective judgment [8, 9, 10]. An objective approach that uses personalized neurophysiological measurements to optimize DBS programming is therefore highly demanded.
As a neurodegenerative disease, PD damages the central nervous system and its function, leading to movement disorders. While DBS improves motor symptoms, changes with respect to brain function definitely happen. Brain functional connectivity (BFC) refers to the statistical correlation between physiological signals from PD-related brain regions, might characterize DBS-induced functional variation and provide a quantified and objective measure for DBS treatment. Different brain regions communicate and coordinate during function fulfillment and task execution, and brain functional connectivity represents this effort [11, 12, 13]. Algorithms have been developed for BFC analysis of neurological disorders [14, 15]. With the DBS treatment, the BFC strength indicates the ‘cost’ of the brain while the patient trying to complete a specific task. The lower the cost, the higher communication efficiency among the brain regions, and the better the DBS parameters might be. In this paper, we verify this idea by clinical tests of PD patients.

To investigate the brain activation of PD patients, previous studies have applied SPECT [16, 17], PET [18], fMRI [19, 20] and EEG [21, 22], mainly by comparison between patients and the healthy controls for diagnosis, but none for DBS programming. Moreover, none of fMRI, SPECT or PET could allow ‘task-state’ measurements while the patient trying to complete a motor task, and the preparation process for EEG measurement is tedious and challenging for PD patients after DBS surgery, restricting the possibilities for these imaging modalities to be applied in DBS programming. Instead, functional near-infrared spectroscopy (fNIRS) is an optical functional neuroimaging technique that uses near-infrared light (700-900 nm spectral interval) to perform continuous and non-invasive monitoring of blood hemoglobin changes related to brain functions [23]. The fNIRS-based functional connectivity has been successfully used in clinical applications. In [24], Qitao et al. assessed resting-state functional connectivity in cerebral infarction patients with fNIRS. In [25], Didem et al. used functional connectivity features to perform clinical binary classification in patients with fibromyalgia. A further advantage for our study is that the fNIRS equipment can be made portable, enabling ‘task-state’ measurements during clinical evaluation such as walking.

With a wearable fNIRS system, we measured five PD patients in the clinical DBS programming process, recording their brain activities during standard walking tests under different brain stimulation frequencies that were specified by the doctors. The fNIRS-based brain functional connectivity analysis was conducted on three brain regions: the prefrontal cortex, parietal lobe, and occipital lobe. The coordination and communication among these brain regions are essentially evolved during the walking test in clinical DBS programming and their functional connectivity can characterize DBS-induced improvement of neural function.

**Methods**

**Participants**

The patients of consideration were clinically diagnosed idiopathic Parkinson’s disease without other plus syndromes. Exclusion criteria for patient recruitment include: (1) unnecessary to re-adjust the stimulation parameters; (2) unable to stand or walk for 90s at a time; (3) any factors affecting their gait performance, such as idiopathic scoliosis and leg injury; (4) any mental diseases, such as neuropsychiatric comorbidity, schizophrenia and personality disorders; and (5) age > 70 years. Five PD patients that received DBS surgery and qualified for the study were recruited. These PD patients had bilateral symptoms and were treated with bilateral stimulation. Each patient was fully informed of the experimental purpose and procedures, and provided written consent prior to the measurement. The clinical characteristics and initial stimulation parameters in the DBS surgery of these patients are shown in Table 1.

**Functional Near-Infrared Spectroscopy**

A wearable, wireless, continuous-wave fNIRS system (Nirsmart, Danyang Huichuang Medical Equipment Co, Ltd, China) [26] was used to monitor the concentration change of oxygenated hemoglobin ($\Delta HbO_2$). The wavelength of the near-infrared light was 760nm, and the sampling rate was 10Hz. Six regions, i.e., left
Table 1: Clinical characteristics of the five PD patients for DBS programming

| Patient | Age | Gender | Stimulated Target | Insertion Time | Medication Duration | Hoehn-Yahr Scale | MDS-UPDRS III | MOCA |
|---------|-----|--------|-------------------|----------------|---------------------|-----------------|--------------|------|
| P1      | 61  | Male   | Subthalamic Nucleus | 12 Months     | 5 Years             | 3               | 36           | 21   |
| P2      | 58  | Female | Subthalamic Nucleus | 11 Months     | 16 Years            | 4               | 102          | 24   |
| P3      | 58  | Female | Subthalamic Nucleus | 6 Months      | 5 Years             | 3               | 42           | 24   |
| P4      | 60  | Female | Subthalamic Nucleus | 8 Months      | 11 Years            | 3               | 52           | 24   |
| P5      | 63  | Female | Subthalamic Nucleus | 6 Months      | 6 Years             | 3               | 60           | 22   |

*a* Insertion time: the time after the DBS electrode insertion.

and right prefrontal cortex (L/R-PFC), parietal lobe (L/R-PL), and occipital lobe (L/R-OL) were chosen as the areas of interest for recording, and 34 fNIRS electrodes including 16 sources and 18 detectors were placed to the selected region, as shown in Figure 2. The prefrontal cortex is implicated in cognitive control and information processing for complex behavior. The parietal lobe plays an important role in motor function, working memory, and the integration of multiple sensory information. The occipital lobe is responsible for visual processing, working memory, and modulation of different sensory stimulation.

**Experimental Design**

The crucial brain stimulation parameters in DBS programming consist of the location of electrode contact, voltage amplitude and frequency. In our experiments, the DBS frequency was varied while the location of electrode contact and voltage amplitude were invariant. The reasons of only varying DBS frequency included: (1) The locations of electrode contact had been optimized by doctors with MRI scans and 3D reconstruction technique. The voltage amplitudes were fixed by the doctors with clinical diagnosis. (2) DBS frequency was related to the improvement of gait and balance [27, 28, 29, 30]. After varying the DBS frequency, the patients performed the walking test, as shown in Figure 3. It has to be noted that DBS patients are normally not strong enough to take too many walking tests. For the five PD patients of this study, we limited the number of walking tests to be 4 at most. The process of the walking test was: 1) the doctor performed the frequency adjustment, 2) the patient sat on a chair for 5 minutes to ensure that the new DBS paradigm actually took effect, 3) the patient stood up from the chair, and stood quite for 30s, 4) the patient performed the 10-meter walking task, and 5) the patient stood quite for 30s again. Instructions of “Standing”, “Walking”, “Stop” and “Finish” were given by the doctors during each test. PD patients were tested under medicine off condition.

**Data Processing**

**Preprocessing**

Firstly, the collected fNIRS measurement data were processed with a 0.01-0.2 bandpass filter to remove the instrumental and physiological noises (e.g. heartbeats, respirations and Mayer waves) [31, 32, 33]. Then, the $\triangle HbO_2$ of each channel was calculated with the filtered data according to the modified Beer-Lambert law [34]. Further, Motion artifacts were removed based on moving standard deviation and spline interpolation [35].

**Functional Connectivity and Global Efficiency**

Firstly, the Pearson’s correlation coefficient $P_{C_xC_y}$ between two channels was calculated as follows:

$$P_{C_xC_y} = \frac{\text{cov}(C_x, C_y)}{\sigma_{C_x}\sigma_{C_y}} = \frac{\sum_{i=1}^{m}(C_{x,i} - \bar{C}_x)(C_{y,i} - \bar{C}_y)}{\sqrt{\sum_{i=1}^{m}(C_{x,i} - \bar{C}_x)^2}\sqrt{\sum_{i=1}^{m}(C_{y,i} - \bar{C}_y)^2}}$$

(1)

where $C_x$ and $C_y$ are the measurements ($\triangle HbO_2$) of the $x$-th and $y$-th channels, $\text{cov}(C_x, C_y)$ is the covariance between $C_x$ and $C_y$, $\sigma_{C_x}$ and $\sigma_{C_y}$ are the
standard deviation of $C_x$ and $C_y$. $m$ is the length of the measurement, $C_{x,i}$ and $C_{y,i}$ are the $i$-th measurement ($\triangle HbO_2$) of the $x$-th and $y$-th channels, and $\bar{C}_x = \frac{1}{m} \sum_{i=1}^{m} C_{x,i}$ and $\bar{C}_y = \frac{1}{m} \sum_{i=1}^{m} C_{y,i}$ are the average values of $C_x$ and $C_y$.

Then, Fisher’s $z$-transformation was applied to decrease the skewness of $P_{C_x C_y}$ and normalize its distribution:

$$F_{C_x C_y} = \text{artanh}(P_{C_x C_y}) = \frac{1}{2} \ln \left( \frac{1 + P_{C_x C_y}}{1 - P_{C_x C_y}} \right) \quad (2)$$

where $F_{C_x C_y}$ is the connection strength between channel $C_x$ and $C_y$, and $\text{artanh}(\cdot)$ is the inverse hyperbolic tangent function. The $F_{C_x C_y}$ values were used to construct the connectivity matrix $M$, which is defined as follows:

$$M = \begin{bmatrix} F_{C_1 C_1} & F_{C_1 C_2} & \cdots & F_{C_1 C_N} \\ \vdots & \vdots & & \vdots \\ F_{C_N C_1} & F_{C_N C_2} & \cdots & F_{C_N C_N} \end{bmatrix} \quad (3)$$

where $N$ is the channel number of global brain regions.

It should be noted that higher connection strength in the connectivity matrix $M$ corresponds to lower brain communication efficiency [36, 37, 38].

Further, the global efficiency ($GE$) describes the overall communication efficiency:

$$GE = \frac{1}{N} \sum_{x=1}^{N} \frac{1}{\sum_{y=1, y \neq x}^{N} F_{C_x C_y}} \quad (4)$$

where $N$ is the channel number of global brain regions. $C_x$ and $C_y$ indicate the measurement ($\triangle HbO_2$) of the $x$-th and $y$-th channels. $F_{C_x C_y}$ indicates the connection strength between channel $C_x$ and $C_y$. Higher $GE$ scores represent lower communication strength of global regions.

**Local Strength**

Local strength represents the communication strength between different brain regions. The local strength of PFC, PL and OL is respectively defined as $LS_{PFC}$, $LS_{PL}$ and $LS_{OL}$, i.e.,

$$LS_{PFC} = \frac{1}{2} \left( \frac{1}{N_{LPPC} \times N} \sum_{x=1}^{N_{LPPC}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \right) + \frac{1}{N_{RPPC} \times N} \sum_{x=1}^{N_{RPPC}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \quad (5)$$

$$LS_{PL} = \frac{1}{2} \left( \frac{1}{N_{LPPL} \times N} \sum_{x=1}^{N_{LPPL}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \right) + \frac{1}{N_{RPPL} \times N} \sum_{x=1}^{N_{RPPL}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \quad (6)$$

$$LS_{OL} = \frac{1}{2} \left( \frac{1}{N_{LOL} \times N} \sum_{x=1}^{N_{LOL}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \right) + \frac{1}{N_{ROL} \times N} \sum_{x=1}^{N_{ROL}} \sum_{y=1, y \neq x}^{N} F_{C_x C_y} \quad (7)$$
where \( N \) is the channel number of global brain regions. \( N_{LPFC}, N_{RPFC}, N_{LPL}, N_{RPL}, N_{LOI} \) and \( N_{ROL} \) indicate the channel number of LPFC, RPFC, LPL, RPL, LOI and ROL, respectively. Moreover, the averaged local strength (\( \text{L}_{\text{aver}} \)) is defined as follows:

\[
\text{L}_{\text{aver}} = \frac{N_{PFC}}{N} \times L'_{PFC} + \frac{N_{PL}}{N} \times L'_{PL} + \frac{N_{OL}}{N} \times L'_{OL} \quad (8)
\]

where \( N_{PFC}, N_{PL}, \) and \( N_{OL} \) indicate the channel number in PFC, PL and OL. \( L'_{PFC}, L'_{PL} \) and \( L'_{OL} \) represent the normalized \( L_{PFC}, L_{PL} \) and \( L_{OL} \), respectively. \( L'_{PFC}, L'_{PL} \) and \( L'_{OL} \) are defined as follows:

\[
L'_{PFC} = \frac{L_{PFC} - L_{\text{min}}^{PFC}}{L_{\text{max}}^{PFC} - L_{\text{min}}^{PFC}} \quad (9)
\]

\[
L'_{PL} = \frac{L_{PL} - L_{\text{min}}^{PL}}{L_{\text{max}}^{PL} - L_{\text{min}}^{PL}} \quad (10)
\]

\[
L'_{OL} = \frac{L_{OL} - L_{\text{min}}^{OL}}{L_{\text{max}}^{OL} - L_{\text{min}}^{OL}} \quad (11)
\]

Table 2 The local functional connectivity analysis

| Patient | Frequencies | \( L_{PFC} \) | \( L_{PL} \) | \( L_{OL} \) | \( \text{L}_{\text{aver}} \) |
|---------|-------------|---------------|---------------|---------------|----------------|
| P1      | 125Hz       | 0.3679        | 0.3524        | 0.1865        | 0.0306         | 2.8253         |
|         | 100Hz       | 0.3217        | 0.4393        | 0.3969        | 0.1538         | 2.4961         |
|         | 80Hz        | 0.3447        | 0.3591        | 0.4269        | 0.1339         | 2.3683         |
|         | 60Hz        | 0.9445        | 0.9246        | 0.6804        | 1.0000         | 1.0446         |
| P2      | 130Hz       | 0.1193        | 0.3374        | 0.1929        | 0.0693         | 3.4236         |
|         | 160Hz       | 0.3052        | 0.4393        | 0.2356        | 0.4559         | 2.8045         |
|         | 185Hz       | 0.3887        | 0.3382        | 0.1570        | 0.3672         | 2.7523         |
|         | 100Hz       | 0.1966        | 0.4459        | 0.1874        | 0.6479         | 2.5749         |
| P3      | 100Hz       | 0.0971        | 0.3370        | 0.2609        | 0.0467         | 4.0123         |
|         | 80Hz        | 0.2135        | 0.3614        | 0.1784        | 0.1677         | 3.3139         |
|         | 60Hz        | 0.4024        | 0.4137        | 0.1757        | 0.4549         | 2.3944         |
|         | 125Hz       | 0.4348        | 0.6311        | 0.5208        | 1.0000         | 1.7739         |
| P4      | 160Hz       | 0.3211        | 0.2568        | 0.3267        | 0.2162         | 3.3366         |
|         | 130Hz       | 0.3493        | 0.3416        | 0.1224        | 0.3598         | 2.9649         |
|         | 60Hz        | 0.4027        | 0.3632        | 0.0804        | 0.5598         | 2.7418         |
|         | 80Hz        | 0.4260        | 0.4174        | 0.2646        | 0.9455         | 2.3951         |
| P5      | 130Hz       | 0.1289        | 0.3812        | 0.3502        | 0.1330         | 3.5287         |
|         | 80Hz        | 0.2989        | 0.3229        | 0.2711        | 0.2999         | 3.1407         |
|         | 60Hz        | 0.3877        | 0.2994        | 0.5130        | 0.3953         | 2.7492         |
|         | 160Hz       | 0.2315        | 0.4699        | 0.4734        | 0.7431         | 2.5838         |

Comparison with Clinical Assessments

The proposed quantified assessment based on task fNIRS measurements and brain functional analysis was compared with clinical assessments including the on-site DBS programming decisions and post-independent MDS-UPDRS ratings on the recorded videos of walking tests. The DBS programming decision, MDS-UPDRS ratings, and analysis on brain functional efficiency were conducted independently from each other, and the relative results were not revealed to the personnel performing other analysis until the entire study was accomplished. The results are shown in Table 3.
Figure 4 The brain functional connectivity matrices calculated from the fNIRS measurements of the five PD patients (P1, P2, P3, P4, P5) at different DBS frequencies. The color bar corresponding to the values of CM was presented at the bottom. The frequency values in red are promisingly optimal for each patient.
Table 3 Comparison of brain efficiency with clinical assessments including the on-site DBS programming decisions and post independent MDS-UPDRS ratings based on the recorded videos.

| Patient | DBS Machines<sup>a</sup> | Electrode Contact, Voltage, and Impulse Duration<sup>a,b</sup> | Frequencies | Optimal Frequency Determined by the Doctors <sup>c,d,e</sup> | MDS-UPDRS Scores<sup>f</sup> | Brain Global Efficiency<sup>g</sup> |
|---------|-------------------------|-------------------------------------------------|-------------|-------------------------------------------------|----------------|-----------------------------|
| P1      | Medtronic               | Left Hemisphere: (10, 2.9V, 90µs)               | 125Hz       | 1 1 1                                           | 2.8253         |
|         |                         | (11, 2.7V, 60µs)                                | 100Hz       | 2 1 1.5                                         | 2.4961         |
|         |                         | Right Hemisphere: (2, 2.7V, 60µs)               | 80Hz        | 2 2 2                                           | 2.3683         |
|         |                         | (3, 2.5V, 60µs)                                | 60Hz        | 2 2 2                                           | 1.0446         |
| P2      | PINS                    | Left Hemisphere: (6, 2.7V, 60µs)                | 130Hz       | 1 1 1                                           | 3.4236         |
|         |                         | Right Hemisphere: (2, 2.7V, 60µs)              | 160Hz       | 1 1 1                                           | 2.8045         |
|         |                         | (2, 2.7V, 60µs)                                | 185Hz       | 1 1 1                                           | 2.7523         |
|         |                         | (2, 2.7V, 60µs)                                | 100Hz       | 1 1 1                                           | 2.5749         |
| P3      | Medtronic               | Left Hemisphere: (10, 2V, 80µs)                | 100Hz       | 1 1 1                                           | 4.0123         |
|         |                         | (8, 2V, 60µs)                                  | 80Hz        | 1 1 1                                           | 3.3139         |
|         |                         | Right Hemisphere: (2, 1.7V, 60µs)              | 60Hz        | 1 1 1                                           | 2.3944         |
|         |                         | (2, 1.7V, 60µs)                                | 125Hz       | 1 1 1                                           | 1.7739         |
| P4      | Medtronic               | Left Hemisphere: (9, 1.8V, 60µs)               | 160Hz       | 1 1 1                                           | 3.3366         |
|         |                         | Right Hemisphere: (3, 2.5V, 60µs)              | 130Hz       | 1 1 1                                           | 2.9649         |
|         |                         | (3, 2.5V, 60µs)                                | 60Hz        | 2 1 1.5                                         | 2.7418         |
|         |                         | (3, 2.5V, 60µs)                                | 80Hz        | 2 1 1.5                                         | 2.3951         |
| P5      | PINS                    | Left Hemisphere: (4, 3V, 60µs)                 | 130Hz       | 1 1 1                                           | 3.5287         |
|         |                         | Right Hemisphere: (6, 3V, 60µs)                | 80Hz        | 1 1 1                                           | 3.1407         |
|         |                         | (6, 3V, 60µs)                                  | 60Hz        | 1 1 1                                           | 2.7492         |
|         |                         | (6, 3V, 60µs)                                  | 160Hz       | 1 1 1                                           | 2.5838         |

<sup>a</sup> Definition of electrode contact points depends on the DBS machines.

<sup>b</sup> The location and number of stimulation points were determined by the doctors.

<sup>c</sup> These frequencies were the doctors’ on-site decision in DBS programming and actually used for treatment.

<sup>d</sup> The optimal frequencies were determined by doctors considering the rigidity, tremor, gait and patients’ feeling. In the experiments, the optimal frequencies determined by doctors were consistent the frequencies that patients felt the most comfortable.

<sup>e</sup> One-month follow-up after DBS programming reported that all the five patients were satisfied with the DBS treatment, and no adverse effect or feelings was reported or noticed by the patients, their families, or doctors.

<sup>f</sup> The MDS-UPDRS scores were rated by two qualified and experienced doctors, based on the recorded videos on patient performance during DBS programming.

<sup>g</sup> The DBS programming decision, MDS-UPDRS ratings, and GE analysis were conducted independently from each other, and the relative results were not revealed to the personnel performing other analysis until the entire study was accomplished.
For all the five patients, the doctors’ on-site decision on DBS frequency were consistent with the optimal frequency by the brain functional connectivity analysis, i.e., the one that corresponds to both the highest global efficiency and lowest local connection strength. The doctors made the decisions according to the following clinical process [39, 40]: (1) assessing the rigidity and tremor of PD patients; (2) measuring the gait performance with MDS-UPDRS ratings; (3) communicating with patients about their comprehensive feeling such as comfortability, etc; (4) choosing the best DBS frequency considering the rigidity, tremor, gait and patients’ feeling. In the experiments, the doctors’ on-site decision on DBS frequency were consistent with frequencies that patients felt the most comfortable. One-month follow-up after DBS programming reported that all patients were satisfied with the DBS treatment, and no adverse effect or feelings was reported or noticed by the patients, their families, or doctors. The dopaminergic medication was unchanged during the one-month follow-up period.

MDS-UPDRS, the Unified Parkinson’s Disease Rating Scale by the Movement Disorder Society, has been universally used in clinical assessment on motor and non-motor aspects of Parkinson’s disease [41]. The videos of the five patients while performing the walking tests were sent to two qualified specialists, S1 and S2, who are experienced on gait assessment of PD patients and independent from this study. The MDS-UPDRS scores include 5 subratings, i.e., 0, 1, 2, 3 and 4, indicating normal, slight, mild, moderate, and severe symptoms, respectively. For all the five patients, both specialists gave the same MDS-UPDRS scores of 1, indicating slight movement disorder, for the patients’ walking performance under the applied DBS treatments that were also consistent with the best brain efficiency. This verified the efficacy of the DBS treatments and brain functional analysis. Nevertheless, the MDS-UPDRS scores were unable to further discriminate less significant differences in motor performance. For all the tested frequencies of patients P2, P4 and P5, both specialists gave the same MDS-UPDRS scores. For the performance differences that could be distinguished by the MDS-UPDRS scores, as patients P1 and P3, the results were all consistent with the brain functional analysis.

**Discussion**

Starting from the fact that Parkinson’s disease is a neurological disorder and implicates motor performance, we proposed in this paper an objective and quantitative assessment method for DBS programming with task fNIRS measurements and brain functional connectivity analysis. To the best of our knowledge, this is the first fNIRS-based study on assessment and optimization of DBS therapy via recording of brain activation while performing motor tasks and analysis on global as well as regional brain efficiency. The methods were developed for post-operative DBS programming, but also has the potential for intra-operative assessment on correct targeting.

Brain functional analysis has been a long-time research focus of Parkinson’s disease. In [18], Rascol et al. measured the regional cerebral blood flow changes with PET during the execution of a finger-to-thumb opposition motor task in the cerebellar hemisphere of parkinsonian patients. Compared with healthy controls, Parkinson’s patients had increased brain activation in ipsilateral cerebellar hemisphere. In [42], Sabetini et al. analyzed the cortical change of PD patients in a complex sequential motor task with fMRI. Compared with normal controls, PD patients had a significant bilateral increase of fMRI signals in the primary sensorimotor cortex, lateral premotor cortex, inferior parietal cortex, caudal part of SMA and anterior cingulate cortex. In [19], Zhang et al. analyzed the functional connectivity of ventral intermediate nucleus of thalamus (Vim) in tremor-dominant (TD) and akinetic-/rigid-dominant (ARD) PD patients with fMRI. In TD patients, the Vim nucleus had an increase of brain connectivity with dentate nucleus, primary motor cortex (M1), SMA, globus pallidus, premotor cortex and parietal cortex compared with normal controls. In ARD patients, the Vim nucleus only exhibited increased connectivity with globus pallidus and limbic lobe compared with normal controls. In [20], Hou et al. evaluated the functional connectivity of default mode network (DMN) with resting-state fMRI data, and found significantly increased connectivities of anterior DMN and prefrontal regions. The common finding of these studies is that PD patients are characterized with hypoactivation of SMA and hyperactivation of cortical motor regions (e.g. primary motor cortex, premotor cortex, parietal cortex) compared with normal controls. DBS can relatively normalize the hypoactivation of SMA and hyperactivation of other cortical regions and optimize the network profile toward healthy controls [43, 44]. Our findings are consistent with these studies. Effective DBS parameters could induce strong normalization and decrease the ‘extra’ brain activation of PD patients in order to optimize the network profile toward healthy controls.

Gait performance is a primary concern for the patients and doctors. Therefore, we took the clinical 10-meter walking test as the motor task for assessment, and accordingly the DBS frequency as the varying parameter since it is directly associated with gait [28]. Other DBS parameters, the location of electrode contact, voltage amplitude and impulse duration, as well
as other motor and non-motor functions, are also important and can be addressed in future studies. The type and number of motor tasks are constrained by the patients’ physical condition.

Besides fNIRS, EEG can also measure brain activation for functional analysis of Parkinson’s disease, but typically for non-motor functions such as cognition [45] and emotion [46]. Technical challenges for EEG measurement during motor tasks include motion artifact and noise removal, source localization, fast set-up, etc. Although fMRI prohibits entry of DBS patients due to the electromagnetic fields, its excellent localization accuracy can facilitate brain functional analysis of PD patients without DBS for non-motor and motor tasks, as it has done to investigate rehabilitation induced brain reorganization after stroke with upper and lower extremity movements assisted by special mechatronic systems [47, 48].

A major limitation of this study is the small number of patients. Nevertheless, our experiment design and analysis method were based on the current understanding of the neurological mechanism of Parkinson’s disease, and the results were in line with this knowledge and also consistent across all the five patients. We hope this work can encourage more study, and more clinical evidence will promisingly enable quantified and individualized optimization of deep brain stimulation therapy for each Parkinson’s patient.

Conclusions
This was a pilot study on quantified assessment of DBS programming. For the first time, we recorded the brain signals of PD patients in clinical DBS programming process with a wearable fNIRS system, and analyzed the collected signals for brain functional connectivity. Experimental results showed that fNIRS assessments and brain functional connectivity analysis promised an objective solution for patient-specific optimization of DBS treatment.

Abbreviations
DBS: Deep brain stimulation; PD: Parkinson’s disease; fNIRS: Functional near-infrared spectroscopy; PFC: Prefrontal cortex; PL: Parietal lobe; OL: Occipital lobe; GE: Global efficiency; CM: Connectivity matrix.

Acknowledgements
The authors would like to thank Ms. Yuanyuan Cheng and Ms. Yue Wang from Tianjin Huanhu Hospital for their help in assessment of the task performance videos. The authors would express their sincere gratitude to all the patients who participated in this study and made the discovery possible.

Funding
This work was supported by the National Natural Science Foundation of China (U1913208, 61873135, 61720106012) and the fundamental research funds for the central universities.

Availability of data and materials
Data that support the findings and software codes developed for the data analysis in this paper will be made available upon reasonable request to the corresponding authors.

Ethics approval and consent to participate
The study was approved by the Ethical Committee of Tianjin Huanhu Hospital (2019-35), and has been registered in Chinese Clinical Trial Registry (ChiCTR1900022715). Each patient was fully informed of the experimental purpose and procedures, and provided written consent prior to the measurement.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable

Authors’ contributions
N. Yu, J. Lu, S. Liang designed the experiments and interpreted the results. N. Yu, J. Lu, Z. Shu, H. Li, Y. Yu and S. Liang performed the experiments with input from J. Wu and J. Han. N. Yu, J. Lu and J. Han analyzed the data and wrote the manuscript. All authors provided feedback on the manuscript.

Authors’ information
Not applicable

Author details
1 College of Artificial Intelligence. Nankai University, Tianjin, China.
2 Tianjin Key Laboratory of Intelligent Robotics, Nankai University, Tianjin, China.
3 Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China.
4 Department of Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin, China.
5 Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China.
6 Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Neurosurgical Institute, Tianjin Huanhu Hospital, Tianjin, China.

References
1. Lang, A.E., Lozano, A.M.: Parkinson’s disease. New England Journal of Medicine 339(16), 1130–1143 (1998)
2. Jankovic, J.: Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 79(4), 368–376 (2008)
3. Zis, P., Erro, R., Walton, C.C., Sauerbier, A., Chaudhuri, K.R.: The range and nature of non-motor symptoms in drug-naive parkinson’s disease patients: a state-of-the-art systematic review. NPJ Parkinson’s Disease 1(1), 1–8 (2015)
4. Bouthour, W., Mégervand, P., Donoghue, J., Lüscher, C., Birbaumer, N., Krack, P.: Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond. Nature Reviews Neurology 15(6), 343–352 (2019)
5. Lozano, A.M., Lipsman, N., Bergman, H., Brown, P., Chabardes, S., Chang, J.W., Matthews, K., McIntyre, C.C., Schlaepfer, T.E., Schuller, M., et al.: Deep brain stimulation: current challenges and future directions. Nature Reviews Neurology 15(4), 148–160 (2019)
6. Benabid, A.L.: Deep brain stimulation for Parkinson’s disease. Current Opinion in Neurobiology 13(6), 696–706 (2003)
7. Perlmuter, J.S., Mink, J.W.: Deep brain stimulation. Annual Review of Neuroscience 29, 229–257 (2006)
8. Grossi, S., Wojtecki, L., Sündmeyer, M., Schnitzler, A.: Deep brain stimulation in Parkinson’s disease. Therapeutic Advances in Neurological Disorders 2(6), 379–391 (2009)
9. Chen, S., Gao, G., Feng, T., Zhang, J.: Chinese expert consensus on programming deep brain stimulation for patients with Parkinson’s disease. Translational Neurodegeneration 7(1), 11 (2018)
10. Koeglspenger, T., Palleis, C., Hell, F., Mehrkens, J.H., Boetzler, K.: Deep brain stimulation programming for movement disorders: Current concepts and evidence-based strategies. Frontiers in Neurology 10, 410 (2019)
11. Caspi, A., Moffitt, T.E.: Gene–environment interactions in psychiatry: joining forces with neuroscience. Nature Reviews Neuroscience 7(7), 583–590 (2006)
12. Van Den Heuvel, M.P., Pol, H.E.H.: Exploring the brain network: a review on resting-state fMRI functional connectivity. European Neuropsychopharmacology 20(8), 519–534 (2010)
13. Friston, K.J.: Functional and effective connectivity: a review. Brain Connectivity 1(1), 13–36 (2011)
28. Xie, T., Vigil, J., MacCracken, E., Gasparaitis, A., Young, J., Kang, 16. Benamer, H.T., Patterson, J., Wyper, D.J., Hadley, D.M., Macphee, 29. Zibetti, M., Moro, E., Krishna, V., Sammartino, F., Picillo, M., 17. Sommer, U., Hummel, T., Cormann, K., Mueller, A., Frasnelli, J., 27. Jia, F., Guo, Y., Wan, S., Chen, H., Hao, H., Zhang, J., Li, L. 25. Gokcay, D., Eken, A., Baltaci, S.: Binary classification using neural and 24. Tan, Q., Zhang, M., Wang, Y., Xin, Q., Wang, B., Li, Z.: Frequency-specific functional connectivity revealed by wavelet-based coherence analysis in elderly subjects with cerebral infarction using nirs method. Medical Physics 42(9), 5391–5403 (2015) 26. Wang, Z., Zhou, Y., Chen, L., Gu, B., Yi, W., Liu, S., Xu, M., Qi, H., He, F., Ming, D.: BCI monitor enhances electrophysiological and cerebral hemodynamic activations during motor training. IEEE Transactions on Neural Systems and Rehabilitation Engineering 27(4), 780–787 (2019) 27. Jia, F., Gu, Y., Wan, S., Chen, H., Hao, H., Zhang, J., Li, L.: Variable frequency stimulation of subthalamic nucleus for freezing of gait in parkinson’s disease. Parkinsonism & related disorders 21(12), 1471–1472 (2015) 28. Xie, T., Vigil, J., MacCracken, E., Gasparaitis, A., Young, J., Kang, W., Bernard, J., Warneke, P., Kang, U.J.: Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 84(4), 415–420 (2015) 29. Zibetti, M., Moro, E., Krishna, V., Sammartino, F., Picillo, M., Munhoz, R.P., Lozano, A.M., Fasano, A.: Low-frequency subthalamic stimulation in parkinson’s disease: long-term outcome and predictors. Brain Stimulation 9(5), 774–779 (2016) 30. Jia, F., Hu, W., Zhang, J., Shukla, A.W., Almeida, L., Meng, F.-g., Okun, M.S., Li, L.: Variable frequency stimulation of subthalamic nucleus in parkinson’s disease: Rationale and hypothesis. Parkinsonism & related disorders 39, 27–30 (2017) 31. Hu, X., Zhuang, C., Wang, F., Liu, Y.-J., Im, C.-H., Zhang, D.: fNIRS evidence for recognizably different positive emotions. Frontiers in Human Neuroscience 13 (2019) 32. Klein, F., Kranczioch, C.: Signal processing in fNIRS: A case for the removal of systemic activity for single trial data. Frontiers in Human Neuroscience 13, 331 (2019) 33. Huo, C., Li, X., Jing, J., Ma, Y., Li, W., Wang, Y., Liu, W., Fan, Y., Yue, S., Wang, Y., et al.: Median nerve electrical stimulation-induced changes in effective connectivity in patients with stroke as assessed with functional near-infrared spectroscopy. Neurorehabilitation and Neural Repair 33(12), 1008–1017 (2019) 34. Cope, M., Delpy, D.T.: System for long-term measurement of cerebral blood and tissue oxygenation on newborn infants by near-infra-red transillumination. Medical and Biological Engineering and Computing 26(3), 289–294 (1988) 35. Scholkmann, F., Spichig, S., Muehlemann, T., Wolf, M.: How to detect and reduce movement artifacts in near-infrared imaging using moving standard deviation and spline interpolation. Physiological Measurement 31(5), 649–663 (2010) 36. Latora, V., Marchiori, M.: Efficient behavior of small-world networks. Physical Review Letters 87(19), 198701 (2001) 37. Rubinov, M., Sporns, O.: Complex network measures of brain connectivity: uses and interpretations. Neuroimage 52(3), 1059–1069 (2010) 38. Bullmore, E., Sporns, O.: Complex brain networks: graph theoretical analysis of structural and functional systems. Nature Reviews Neuroscience 10(3), 186–198 (2009) 39. Bronstein, J.M., Tagliati, M., Alterman, R.L., Lozano, A.M., Volkmann, J., Stefani, A., Horak, F.B., Okun, M.S., Foote, K.D., Krak, P., et al.: Deep brain stimulation for parkinson disease: an expert consensus and review of key issues. Archives of neurology 68(2), 165–168 (2011) 40. Picillo, M., Lozano, A.M., Koo, N., Munhoz, R.P., Fasano, A.: Programming deep brain stimulation for parkinson’s disease: the toronto western hospital algorithms. Brain Stimulation 9(3), 425–437 (2016) 41. Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., Stern, M.B., Dodel, R., et al.: Movement disorder society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders 23(15), 2129–2170 (2008) 42. Sabatini, U., Boulanouar, K., Fabre, N., Martin, F., Carel, C., Colonnese, C., Bozzao, L., Berry, I., Montastruc, J., Chollet, F., et al.: Cortical motor reorganization in akinetic patients with parkinson’s disease: a functional MRI study. Brain 123(2), 394–403 (2000) 43. Grafton, S., Turner, R., Desmurget, M., Bakay, R., Delong, M., Vitek, J., Crutcher, M.: Normalizing motor-related brain activity: subthalamic nucleus stimulation in parkinson disease. Neurology 66(8), 1192–1199 (2006) 44. Horn, A., Wenzel, G., Irmen, F., Huelb, J., Li, N., Neumann, W.-J., Krause, P., Bohner, G., Scheel, M., Kühn, A.A.: Deep brain stimulation induced normalization of the human functional connectome in parkinson’s disease. Brain 142(10), 3129–3143 (2019) 45. Hassan, M., Chaton, L., Benquet, P., Delval, A., Leroy, C., Plomhause, L., Moonen, A.J., Dufts, A.A., Lextjens, A.F., van Kranen-Mastenbroek, V., et al.: Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson’s disease. NeuroImage: Clinical 14, 591–601 (2017) 46. Yuvaraj, R., Murugappan, M., Acharya, U.R., Adeli, H., Ibrahim, N.M., Mesquita, E.: Brain functional connectivity patterns for emotional state classification in Parkinson’s disease patients without dementia. Behavioural Brain Research 298, 248–260 (2016) 47. Yu, N., Estévez, N., Hepp-Reymond, M.-C., Kollías, S.S., Rieder, N.: fMRI assessment of upper extremity related brain activation with an MRI-compatible manipulandum. International Journal of Computer Assisted Radiology and Surgery 6(3), 447–455 (2011) 48. Jaeger, L., Marchal-Crespo, L., Wolf, P., Rieder, R., Kollias, S., Michels, L.: Test-retest reliability of fMRI experiments during robot-assisted active and passive stepping. Journal of Neuroengineering and Rehabilitation 12(1), 102 (2015)